Q3 EPS Estimates for Nuvectis Pharma Boosted by Roth Capital

Nuvectis Pharma, Inc. (NASDAQ:NVCT) – Stock analysts at Roth Capital upped their Q3 2025 earnings per share estimates for shares of Nuvectis Pharma in a research report issued to clients and investors on Tuesday, August 12th. Roth Capital analyst J. Aschoff now anticipates that the company will earn ($0.21) per share for the quarter, up from their prior estimate of ($0.22). The consensus estimate for Nuvectis Pharma’s current full-year earnings is ($1.01) per share. Roth Capital also issued estimates for Nuvectis Pharma’s Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.97) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($0.80) EPS and FY2029 earnings at $3.10 EPS.

NVCT has been the subject of several other reports. Wall Street Zen lowered shares of Nuvectis Pharma from a “hold” rating to a “sell” rating in a research report on Sunday, June 29th. HC Wainwright decreased their price target on shares of Nuvectis Pharma from $15.00 to $10.00 and set a “buy” rating for the company in a research report on Monday, August 4th.

Nuvectis Pharma Stock Performance

NASDAQ:NVCT opened at $6.43 on Thursday. The company has a market cap of $163.71 million, a price-to-earnings ratio of -5.50 and a beta of -0.26. Nuvectis Pharma has a twelve month low of $4.44 and a twelve month high of $11.80. The stock has a fifty day simple moving average of $7.65 and a 200-day simple moving average of $8.24.

Nuvectis Pharma (NASDAQ:NVCT) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.05).

Insider Buying and Selling

In other news, major shareholder Marlio Charles Mosseri acquired 28,043 shares of Nuvectis Pharma stock in a transaction that occurred on Wednesday, June 18th. The stock was purchased at an average cost of $8.05 per share, with a total value of $225,746.15. Following the purchase, the insider owned 2,976,203 shares in the company, valued at $23,958,434.15. This trade represents a 0.95% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders acquired 39,045 shares of company stock valued at $314,300. 30.52% of the stock is currently owned by corporate insiders.

Institutional Trading of Nuvectis Pharma

Several hedge funds have recently made changes to their positions in NVCT. Marshall Wace LLP grew its holdings in shares of Nuvectis Pharma by 191.0% during the 4th quarter. Marshall Wace LLP now owns 124,571 shares of the company’s stock worth $674,000 after purchasing an additional 81,757 shares during the period. Northern Trust Corp grew its holdings in shares of Nuvectis Pharma by 68.7% during the 4th quarter. Northern Trust Corp now owns 25,725 shares of the company’s stock worth $139,000 after purchasing an additional 10,472 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Nuvectis Pharma during the 4th quarter worth $34,000. Squarepoint Ops LLC purchased a new position in shares of Nuvectis Pharma during the 4th quarter worth $103,000. Finally, Blue Zone Wealth Advisors LLC purchased a new position in Nuvectis Pharma during the 1st quarter valued at about $102,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.